The research used cutting-edge technology to determine the signature protein profile. The results open the door for increased efficacy of diagnosis and treatment.
A research team in Hospital 57357 discovers a new way to classify some types of bone cancer through the type and quantity of protein existing in the tumor. This was achieved through the usage of the LC MS-MS device, which is a highly advanced technology in the field, to determine the protein signature of the tumor, and the difference between a specimen and another. This work was carried out by theProteomics and Metabolomics Research Program headed by Dr. Sameh Magdeldin, using advanced mass spectrometry technology.
The study featured the examination of the difference between tumor types, on the level of proteins, and discovering the relationship between the tumor’s protein signature and the expected disease evolution and survival rate, for the tumor subtypes.
The research team has already identified differences between bone cancer types, in terms of type and quantity of proteins existing in them, which is a new way that helps increase the accuracy of identifying the tumor type and the expected prognosis, which could be more informative that relying only on pathological tests, revealed Dr. Nouran Al-Shehaby.
About the importance of this research, Dr. Al-Shehaby says that it gives us a more accurate and informative way to classify the type of tumor in some bone cancer cases. It also gives us more valuable and in depth information about the biological operations in the tumor cells, which affects its progression and its severity; hence, directing doctors to the suitable accurate treating medication for every patient and according to the type of tumor he suffers from, which contributes to raising survival rates.
The research team includes Maram Alaa, Nouran Al-Shehaby, Ali Mustafa Anwar, Nesma Farid, Mustafa Shabaan Shawki, Manal Zamzam, Eman Zaki, Ahmed Elghonaimi, Shahenda Elnagar, and Sameh Magdeldin.
Published in Cells Journal
Impact factor 6